Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Celldex Therapeutics, Inc. (CLDX) had Weighted-Average Shares Outstanding (Diluted) of 66.42M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-67.04M |
|
-- |
|
-- |
|
$73.62M |
|
$-73.62M |
|
$6.57M |
|
$-67.04M |
|
$-67.04M |
|
$-67.04M |
|
$-67.04M |
|
$-67.04M |
|
$-67.04M |
|
$-73.62M |
|
$-73.81M |
|
66.42M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
66.42M |
$-1.01 |
|
$-1.01 |
|
| Balance Sheet Financials | |
$604.34M |
|
$4.83M |
|
$44.10M |
|
$648.44M |
|
$46.47M |
|
-- |
|
$3.61M |
|
$50.08M |
|
$598.36M |
|
$571.17M |
|
$598.36M |
|
66.45M |
|
| Cash Flow Statement Financials | |
$-147.00M |
|
$153.65M |
|
$1.04M |
|
$28.36M |
|
$36.04M |
|
$7.68M |
|
$27.31M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-148.44M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.20% |
|
-11.74% |
|
-10.34% |
|
-11.20% |
|
$9.01 |
|
$-2.23 |
|
$-2.21 |
|